Analyzing Insulet (PODD) and Anika Therapeutics (ANIK)

Insulet (NASDAQ:PODD) and Anika Therapeutics (NASDAQ:ANIK) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Valuation & Earnings

This table compares Insulet and Anika Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Insulet $563.82 million 11.00 $3.29 million $0.05 2,078.00
Anika Therapeutics $105.56 million 4.97 $18.72 million $1.84 20.07



Anika Therapeutics has lower revenue, but higher earnings than Insulet. Anika Therapeutics is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Insulet has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.

Profitability

This table compares Insulet and Anika Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Insulet 2.37% 7.01% 1.58%
Anika Therapeutics 27.44% 11.57% 10.68%

Institutional and Insider Ownership

84.7% of Anika Therapeutics shares are owned by institutional investors. 3.5% of Insulet shares are owned by insiders. Comparatively, 3.7% of Anika Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Insulet and Anika Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insulet 0 2 7 1 2.90
Anika Therapeutics 0 2 2 0 2.50

Insulet currently has a consensus price target of $103.80, indicating a potential downside of 0.10%. Anika Therapeutics has a consensus price target of $38.67, indicating a potential upside of 4.70%. Given Anika Therapeutics’ higher probable upside, analysts clearly believe Anika Therapeutics is more favorable than Insulet.

Summary

Anika Therapeutics beats Insulet on 8 of the 15 factors compared between the two stocks.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of drugs over a specified interval of time, at an administered volume. The company sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.